Control Bionics Ltd. · ASX:CBL
Control Bionics — Shareholder Meeting (October 2026)
29 slides from Control Bionics's shareholder meeting presentation, Oct 13, 2026
Slide 1: FY26 Annual General Meeting: The foundations are in place. Now we convert.
CONTROL BIONICS rsonal use only FY26 ANNUAL GENERAL M EETING The foundations are in place. Now we convert. 13 October 2026 | ASX: CBL Stephen Rix, Chair · Jeremy Steele, CEO & Managing Director
Slide 2: Disclaimer
IMPORTANT NOTICE Disclaimer rsonal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into acc
Slide 3: Welcome to the 2026 Annual General Meeting
WELCOME Welcome to the 2026 Annual General Meeting Level 11, 66 Clarence Street, Sydney · 11:00am (AEDT), Tuesday 13 October 2026 rsonal use only BOARD Stephen Rix Jeremy Steele Damian Lismore Prof Rob Heard Prof Nicholas Opie Non-Executive Chair CEO & Managing Director Non-Executive Director Non-Ex
Slide 4: Today's meeting
AGENDA Today's meeting Formal business rsonal use only 1 Financial report and resolutions, as set out in the Notice of Meeting Chair's address 2 Stephen Rix CEO presentation 3 Jeremy Steele: progress against our three strategic pillars Questions 4 Shareholder questions on the business and the resolu
Slide 5: Voting on all resolutions will be by poll
FORMAL BUSINESS Voting on all resolutions will be by poll rsonal use only 1 Who can vote 2 How to vote Shareholders, proxyholders, attorneys and corporate representatives Mark For, Against or Abstain against each resolution on your voting registered on arrival. You received a voting card at registra
Slide 6: Financial statements and reports
FORMAL BUSINESS · ITEM 1 Financial statements and reports No vote is required on this item rsonal use only To receive and consider the Financial Report, the Directors' Report QUESTIONS FOR THE AUDITOR and the Auditor's Report of Control Bionics Limited for the financial Shareholders may ask the audi
Slide 7: Proxy voting summary
FORMAL BUSINESS Proxy voting summary Proxies received by the 11:00am (AEDT) deadline on Sunday, 11 October 2026 rsonal use only CONTROL BIONICS FY26 AGM | 13 October 2026 7
Slide 8: Full Voting Report
4g AUTOMIC ABN: 27 152 260 814 Full Voting Report Control Bionics Annucl General Meeting VALID VOTING FORM. Resolution 1 Remuneration Report 2 Ro-clection of Director — Damian Lismore 2 Re-election of Director — Stephen Rix 4Re-election of Director — Prof Nicholas Opie 5 Approval to issue 1044 087 S
Slide 9: Resolution 1: Remuneration Report
FORMAL BUSINESS · RESOLUTION 1 Resolution 1: Remuneration Report ADVISORY RESOLUTION rsonal use only “That the Remuneration Report for the financial year ended 30 June 2026, as set out in the Directors’ report be adopted.” The vote is advisory and does not bind the Directors or the Company. Votes ca
Slide 10: Resolution 2: Re-election of Director, Damian Lismore
FORMAL BUSINESS · RESOLUTION 2 Resolution 2: Re-election of Director, Damian Lismore ORDINARY RESOLUTION rsonal use only “That Damian Lismore retires by rotation in accordance with Clause 60 of the Company’s Constitution and, being eligible for re-election, be re-elected as a Director.” The Board, o
Slide 11: Resolution 3: Re-election of Director, Stephen Rix
FORMAL BUSINESS · RESOLUTION 3 Resolution 3: Re-election of Director, Stephen Rix ORDINARY RESOLUTION rsonal use only “That Stephen Rix, having been appointed during the last year as a director pursuant to clause 59.1 of the Constitution, retires in accordance with Clause 59.2 of the Company’s Const
Slide 12: Resolution 4: Re-election of Director, Prof Nicholas Opie
FORMAL BUSINESS · RESOLUTION 4 Resolution 4: Re-election of Director, Prof Nicholas Opie ORDINARY RESOLUTION rsonal use only “That Prof Nicholas Opie, having been appointed during the last year as a director pursuant to clause 59.1 of the Constitution, retires in accordance with Clause 59.2 of the C
Slide 13: Resolution 5: Approval to issue 1,044,087 Shares to Stephen Rix
FORMAL BUSINESS · RESOLUTION 5 Resolution 5: Approval to issue 1,044,087 Shares to Stephen Rix ORDINARY RESOLUTION rsonal use only “That, for the purposes of Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 1,044,087 fully paid ordinary Shares to Stephe
Slide 14: Resolution 6: Approval of issue of Options to Executive Director
FORMAL BUSINESS · RESOLUTION 6 Resolution 6: Approval of issue of Options to Executive Director ORDINARY RESOLUTION rsonal use only “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 1,750,000 Options to Jeremy Steele (or his no
Slide 15: Resolution 7: Employee Share Option Plan
FORMAL BUSINESS · RESOLUTION 7 Resolution 7: Employee Share Option Plan ORDINARY RESOLUTION rsonal use only “That, for the purposes of Exception 13 in ASX Listing Rule 7.2, sections 259B(2) and 260C(4) of the Corporations Act and for all other purposes, shareholders approve the issue of options unde
Slide 16: Resolution 8: Additional placement capacity (LR 7.1A)
FORMAL BUSINESS · RESOLUTION 8 Resolution 8: Additional placement capacity (LR 7.1A) SPECIAL RESOLUTION rsonal use only “That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue equity securities up to an additional 10% of its issued capi
Slide 17: A year of reset: new strategy, new capital, a renewed Board
CHAIR'S ADDRESS A year of reset: new strategy, new capital, a renewed Board Stephen Rix, Chair rsonal use only Strategy Capital Governance • Three-pillar strategy set out in May • $9.75m raised in June–July 2026 • Stephen Rix appointed Non-Executive 2026: one neural-signal platform, three placement
Slide 18: What we told you last year, and what we delivered
ACCOUNTABILITY What we told you last year, and what we delivered Priorities set at the November 2025 AGM and in the May 2026 strategy update rsonal use only PRIORITY STATUS OUTCOME Tobii Dynavox and PRC-Saltillo agreements signed January 2026; funded partner sales US wholesale partners DELIVERED und
Slide 19: FY26 was the transition year. FY27 is the growth year.
FINANCIAL PERFORMANCE FY26 was the transition year. FY27 is the growth year. rsonal use only FY26 RESULT FY27 OUTLOOK $4.77m $7.27m +50% FY27 revenue growth on FY26, reaffirmed revenue, down 22% loss after tax Why revenue fell What drives it • Deliberate move in North America from direct retail to p
Slide 20: One neural-signal platform. Three commercial pillars.
OUR STRATEGY One neural-signal platform. Three commercial pillars. The same non-invasive sEMG technology, sold three ways rsonal use only 1 REVENUE ENGINE 2 GROWTH ENGINE 3 LONG-TERM OPTION Assistive NeuroTech Solutions Platform & Medical Communication Technology NeuroNode and iOS speech devices, Ne
Slide 21: The US wholesale channel is built. Volume follows training.
PILLAR 1 · ASSISTIVE COMMUNICATION The US wholesale channel is built. Volume follows training. rsonal use only Tobii Dynavox Rollout extended to additional US states; next WHAT WE HAVE LEARNED ✓ #1 global AAC provider consultant group onboarding in the coming ~1 quarter weeks. from training a partne
Slide 22: Taking the reimbursed wholesale model to Europe
PILLAR 1 · ASSISTIVE COMMUNICATION Taking the reimbursed wholesale model to Europe Germany: our first reimbursed European market, the template for others rsonal use only Mar 2026 Aug 2026 Sep 2026 23 Sep 2026 16 Oct 2026 HMV listing: NeuroNode First Tobii Dynavox Germany Distribution agreement signe
Slide 23: NeuroStrip: ~80 organisations engaged, up from 20 in July
PILLAR 2 · NEUROTECH SOLUTIONS NeuroStrip: ~80 organisations engaged, up from 20 in July Australia, New Zealand, United States, United Kingdom and Europe rsonal use only ~80 ~30 4 0 organisations engaged in live trials paying customers trials ended without conversion Organisations engaged by region
Slide 24: Customer use of NeuroStrip grew five-fold in six months
PILLAR 2 · NEUROTECH SOLUTIONS Customer use of NeuroStrip grew five-fold in six months NeuroStrip app data from 28 customer organisations in five countries, July 2025 to September 2026 rsonal use only CUSTOMER SESSIONS PER QUARTER WHAT THE DATA SHOWS 282 organisations used NeuroStrip 28 through Sept
Slide 25: What the trials have taught us, and how we are converting them
PILLAR 2 · NEUROTECH SOLUTIONS What the trials have taught us, and how we are converting them rsonal use only Rehabilitation leads 1 Clinic sessions average ~90 minutes versus ~20 minutes for sports clubs. ~80 engaged Rehab is where conversion comes first. ~30 in live trials Sport buys a service, no
Slide 26: Capital-light, margin-accretive growth across three pillars
FINANCIAL OUTLOOK Capital-light, margin-accretive growth across three pillars $4.77m $9.75m $6.8m ~$36m rsonal use only FY26 revenue, down 22% raised, June–July 2026 cash at 31 August 2026 market cap PILL AR 1 PILL AR 2 PILL AR 3 Assistive Communication NeuroTech Solutions Platform & Medical Technol
Slide 27: Building the long-term option: data, software, IP and partners
PILLAR 3 · PLATFORM & MEDICAL TECHNOLOGY Building the long-term option: data, software, IP and partners No platform revenue yet. FY27 is about building the assets that create it. rsonal use only Data & telemetry Software & IP Full-spectrum telemetry now streaming raw sEMG data at 4 kHz. Dr NeuroStri
Slide 28: FY27: what we will deliver. Hold us to it.
FY27 FY27: what we will deliver. Hold us to it. We will report against each of these as the financial year progresses rsonal use only 1 Revenue 2 NextLevel OMNI 3 Partner consultants +50% on FY26 Volumes ramping through funded Tobii Dynavox (US and Germany) and partners PRC-Saltillo onboarding FY27
Slide 29: Questions
CONTROL BIONICS rsonal use only EMPOWERMENT THROUGH PROVEN NEUROTECHNOLOGY Questions Jeremy Steele, CEO & Managing Director · jsteele@controlbionics.com Australia +61 433 229 470 · United States +1 (855) 831-7521 · controlbionics.com · ASX: CBL